{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T03:39:23Z","timestamp":1795145963971,"version":"4.10.3"},"reference-count":143,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Leptomeningeal disease (LMD) is a devastating complication of cancer with a particularly poor prognosis. Among solid tumours, malignant melanoma (MM) has one of the highest rates of metastasis to the leptomeninges, with approximately 10\u201315% of patients with advanced disease developing LMD. Tumour cells that metastasise to the brain have unique properties that allow them to cross the blood\u2013brain barrier, evade the immune system, and survive in the brain microenvironment. Metastatic colonisation is achieved through dynamic communication between metastatic cells and the tumour microenvironment, resulting in a tumour-permissive milieu. Despite advances in treatment options, the incidence of LMD appears to be increasing and current treatment modalities have a limited impact on survival. This review provides an overview of the biology of LMD, diagnosis and current treatment approaches for MM patients with LMD, and an overview of ongoing clinical trials. Despite the still limited efficacy of current therapies, there is hope that emerging treatments will improve the outcomes for patients with LMD.<\/jats:p>","DOI":"10.3390\/ijms241411443","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T08:35:47Z","timestamp":1689323747000},"page":"11443","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Leptomeningeal Metastases in Melanoma Patients: An Update on and Future Perspectives for Diagnosis and Treatment"],"prefix":"10.3390","volume":"24","author":[{"given":"Julian","family":"Steininger","sequence":"first","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universit\u00e4t (TU) Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2164-4644","authenticated-orcid":false,"given":"Frank Friedrich","family":"Gellrich","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universit\u00e4t (TU) Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3569-6979","authenticated-orcid":false,"given":"Kay","family":"Engellandt","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universit\u00e4t (TU) Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Meinhardt","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Carl Gustav Carus, Technische Universit\u00e4t (TU) Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Westphal","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universit\u00e4t (TU) Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Beissert","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universit\u00e4t (TU) Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universit\u00e4t (TU) Dresden, 01307 Dresden, Germany"},{"name":"Skin Cancer Center at the University Cancer Center, National Center for Tumor Diseases (NCT\/UCC), 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella C.","family":"Glitza Oliva","sequence":"additional","affiliation":[{"name":"Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/pcmr.12538","article-title":"Melanoma Central Nervous System Metastases: Current Approaches, Challenges, and Opportunities","volume":"29","author":"Cohen","year":"2016","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11060-019-03121-2","article-title":"Predictors of Survival in Metastatic Melanoma Patients with Leptomeningeal Disease (LMD)","volume":"142","author":"Ferguson","year":"2019","journal-title":"J. Neurooncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2174\/157339411797642597","article-title":"Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment","volume":"7","author":"Leal","year":"2011","journal-title":"Curr. Cancer Ther. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ejca.2021.02.016","article-title":"Leptomeningeal Disease from Melanoma-Poor Prognosis despite New Therapeutic Modalities","volume":"148","author":"Chorti","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"10008","DOI":"10.1200\/JCO.2020.38.15_suppl.10008","article-title":"Single-Center Phase I\/Ib Study of Concurrent Intrathecal (IT) and Intravenous (IV) Nivolumab (N) for Metastatic Melanoma (MM) Patients (Pts) with Leptomeningeal Disease (LMD)","volume":"38","author":"Glitza","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/1097-0142(19830101)51:1<154::AID-CNCR2820510130>3.0.CO;2-K","article-title":"Leptomeningeal Carcinomatosis. How Does Cancer Reach the Pia-Arachnoid?","volume":"51","author":"Kokkoris","year":"1983","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1212\/WNL.0000000000000455","article-title":"Teaching NeuroImages: Leptomeningeal Lung Carcinoma","volume":"82","author":"Glover","year":"2014","journal-title":"Neurology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/pgmj.56.653.149","article-title":"Diffuse Involvement of the Leptomeninges by Tumour\u2014A Clinical and Pathological Study of 63 Cases","volume":"56","author":"Boyle","year":"1980","journal-title":"Postgrad. Med. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3340\/jkns.2012.52.3.193","article-title":"Incidence and Risk Factors for Leptomeningeal Carcinomatosis in Breast Cancer Patients with Parenchymal Brain Metastases","volume":"52","author":"Jung","year":"2012","journal-title":"J. Korean Neurosurg. Soc."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Khaled, M.L., Tarhini, A.A., Forsyth, P.A., Smalley, I., and Pi\u00f1a, Y. (2023). Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases. Cancers, 15.","DOI":"10.3390\/cancers15061884"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/1477-7819-12-265","article-title":"Leptomeningeal Metastases from a Primary Central Nervous System Melanoma: A Case Report and Literature Review","volume":"12","author":"Pan","year":"2014","journal-title":"World J. Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jocn.2013.08.018","article-title":"Primary Leptomeningeal Melanoma","volume":"21","author":"Xie","year":"2014","journal-title":"J. Clin. Neurosci."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"DeAngelis, L.M., and Posner, J.B. (2008). Neurologic Complications of Cancer, Oxford University Press.","DOI":"10.1093\/med\/9780195366747.001.0001"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e1236","DOI":"10.1002\/cnr2.1236","article-title":"Leptomeningeal Metastatic Cells Adopt Two Phenotypic States","volume":"5","author":"Remsik","year":"2022","journal-title":"Cancer Rep."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ramakrishna, R., Magge, R.S., Baaj, A.A., and Knisely, J.P.S. (2020). Central Nervous System Metastases: Diagnosis and Treatment, Springer.","DOI":"10.1007\/978-3-030-42958-4"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1126\/science.aay9189","article-title":"The Human Tumor Microbiome Is Composed of Tumor Type\u2013Specific Intracellular Bacteria","volume":"368","author":"Nejman","year":"2020","journal-title":"Science"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature12626","article-title":"Influence of Tumour Micro-Environment Heterogeneity on Therapeutic Response","volume":"501","author":"Junttila","year":"2013","journal-title":"Nature"},{"key":"ref_18","first-page":"1","article-title":"Microbiome Harbored within Tumors: A New Chance to Revisit Our Understanding of Cancer Pathogenesis and Treatment","volume":"5","author":"Zhao","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ccell.2018.03.015","article-title":"The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy","volume":"33","author":"Gopalakrishnan","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor Microenvironment Complexity and Therapeutic Implications at a Glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun. Signal"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/2159-8290.CD-18-1489","article-title":"Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases","volume":"9","author":"Fischer","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.nec.2020.06.011","article-title":"Targeting the Tumor Microenvironment in Brain Metastasis","volume":"31","author":"Giridharan","year":"2020","journal-title":"Neurosurg. Clin. N. Am."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.expneurol.2015.07.027","article-title":"A Balanced View of the Cerebrospinal Fluid Composition and Functions: Focus on Adult Humans","volume":"273","author":"Spector","year":"2015","journal-title":"Exp. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.cell.2017.02.025","article-title":"Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis","volume":"168","author":"Boire","year":"2017","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1158\/1078-0432.CCR-21-1694","article-title":"Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases","volume":"27","author":"Smalley","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1158\/1078-0432.CCR-19-2840","article-title":"Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance","volume":"26","author":"Smalley","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/neuonc\/noac054","article-title":"A Preclinical Model of Patient-Derived Cerebrospinal Fluid Circulating Tumor Cells for Experimental Therapeutics in Leptomeningeal Disease from Melanoma","volume":"24","author":"Law","year":"2022","journal-title":"Neuro Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.4103\/2152-7806.111304","article-title":"Carcinomatous Meningitis: Leptomeningeal Metastases in Solid Tumors","volume":"4","author":"Taillibert","year":"2013","journal-title":"Surg. Neurol. Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1212\/WNL.0b013e31828f183f","article-title":"Rare Cell Capture Technology for the Diagnosis of Leptomeningeal Metastasis in Solid Tumors","volume":"80","author":"Nayak","year":"2013","journal-title":"Neurology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/neuonc\/nor172","article-title":"Role of Flow Cytometry Immunophenotyping in the Diagnosis of Leptomeningeal Carcinomatosis","volume":"14","author":"Serrano","year":"2012","journal-title":"Neuro Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10585-015-9716-3","article-title":"Diagnostic and Prognostic Significance of Flow Cytometry Immunophenotyping in Patients with Leptomeningeal Carcinomatosis","volume":"32","author":"Serrano","year":"2015","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10549-015-3610-1","article-title":"Detection of Cerebrospinal Fluid Tumor Cells and Its Clinical Relevance in Leptomeningeal Metastasis of Breast Cancer","volume":"154","author":"Lee","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/1097-0142(19820215)49:4<759::AID-CNCR2820490427>3.0.CO;2-7","article-title":"Diagnosis and Treatment of Leptomeningeal Metastases from Solid Tumors: Experience with 90 Patients","volume":"49","author":"Wasserstrom","year":"1982","journal-title":"Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jamaoncol.2018.7204","article-title":"Association of Neurosurgical Resection With Development of Pachymeningeal Seeding in Patients With Brain Metastases","volume":"5","author":"Cagney","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/pcmr.12861","article-title":"Leptomeningeal Disease in Melanoma Patients: An Update to Treatment, Challenges, and Future Directions","volume":"33","author":"Glitza","year":"2020","journal-title":"Pigment. Cell. Melanoma Res."},{"key":"ref_36","unstructured":"(2023, July 10). Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Pr\u00e4vention, Diagnostik, Therapie Und Nachsorge Des Lungenkarzinoms, Lang-Version 1.0, 2018, AWMF-Registernummer: 020\/007OL. Available online: http:\/\/Leitlinienprogramm-on-Kologie.de\/Lungenkarzinom.98.0.Html."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the Diagnosis, Staging and Treatment of Patients with Metastatic Breast Cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_38","unstructured":"(2021, August 31). Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF):Diagnostik, Therapie Und Nachsorge Des Melanoms, Langversion 3.3, 2020, AWMF Registernummer: 032\/024OL. Available online: Http:\/\/Www.Leitlinienprogramm-Onkologie.de\/Leitlinien\/Melanom\/."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up\u2606","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(17)30230-9","article-title":"Prophylactic Cranial Irradiation versus Observation in Patients with Extensive-Disease Small-Cell Lung Cancer: A Multicentre, Randomised, Open-Label, Phase 3 Trial","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/0002-9343(83)91019-7","article-title":"Role of Prophylactic Cranial Irradiation in Prevention of Central Nervous System Metastases in Small Cell Lung Cancer: Potential Benefit Restricted to Patients with Complete Response","volume":"74","author":"Rosen","year":"1983","journal-title":"Am. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.lungcan.2004.01.025","article-title":"Multivariate Analysis of Factors Predictive of Brain Metastases in Localised Non-Small Cell Lung Carcinoma","volume":"45","author":"Bajard","year":"2004","journal-title":"Lung Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1200\/JCO.2005.08.026","article-title":"Time from Treatment to Subsequent Diagnosis of Brain Metastases in Stage III Non-Small-Cell Lung Cancer: A Retrospective Review by the Southwest Oncology Group","volume":"23","author":"Gaspar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/neuonc\/noz012","article-title":"Liquid Biopsy in Central Nervous System Metastases: A RANO Review and Proposals for Clinical Applications","volume":"21","author":"Boire","year":"2019","journal-title":"Neuro Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/neuonc\/nox066","article-title":"Cerebrospinal Fluid Circulating Tumor Cells: A Novel Tool to Diagnose Leptomeningeal Metastases from Epithelial Tumors","volume":"19","author":"Lin","year":"2017","journal-title":"Neuro Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s12032-013-0538-3","article-title":"Detection and Quantification of CSF Malignant Cells by the CellSearch Technology in Patients with Melanoma Leptomeningeal Metastasis","volume":"30","author":"Tu","year":"2013","journal-title":"Med. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1615\/CritRevImmunol.v24.i4.40","article-title":"Human High Molecular Weight-Melanoma-Associated Antigen (HMW-MAA): A Melanoma Cell Surface Chondroitin Sulfate Proteoglycan (MSCP) with Biological and Clinical Significance","volume":"24","author":"Campoli","year":"2004","journal-title":"Crit. Rev. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11060-022-03949-1","article-title":"Quantitative Assessment of Circulating Tumor Cells in Cerebrospinal Fluid as a Clinical Tool to Predict Survival in Leptomeningeal Metastases","volume":"157","author":"Diaz","year":"2022","journal-title":"J. Neurooncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-017-2691-6","article-title":"EpCAM-Based Assays for Epithelial Tumor Cell Detection in Cerebrospinal Fluid","volume":"137","author":"Pluim","year":"2018","journal-title":"J. Neurooncol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Pellerino, A., Brastianos, P.K., Rud\u00e0, R., and Soffietti, R. (2021). Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches. Cancers, 13.","DOI":"10.3390\/cancers13122888"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"24677","DOI":"10.18632\/oncotarget.8250","article-title":"Epithelial-to-Mesenchymal Transition Leads to Loss of EpCAM and Different Physical Properties in Circulating Tumor Cells from Metastatic Breast Cancer","volume":"7","author":"Hyun","year":"2016","journal-title":"Oncotarget"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Spis\u00e1k, S., Solymosi, N., Ittz\u00e9s, P., Bodor, A., Kondor, D., Vattay, G., Bart\u00e1k, B.K., Sipos, F., Galamb, O., and Tulassay, Z. (2013). Complete Genes May Pass from Food to Human Blood. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0069805"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Telekes, A., and Horv\u00e1th, A. (2022). The Role of Cell-Free DNA in Cancer Treatment Decision Making. Cancers, 14.","DOI":"10.3390\/cancers14246115"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"800053","DOI":"10.3389\/fonc.2021.800053","article-title":"Challenges and Advances in Diagnosis and Treatment of Leptomeningeal Disease (LMD)","volume":"11","author":"Ferguson","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"100060","DOI":"10.1016\/j.esmoop.2021.100060","article-title":"How to Use Liquid Biopsies to Treat Patients with Cancer","volume":"6","author":"Siravegna","year":"2021","journal-title":"ESMO Open."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1038\/ncomms9839","article-title":"Cerebrospinal Fluid-Derived Circulating Tumour DNA Better Represents the Genomic Alterations of Brain Tumours than Plasma","volume":"6","author":"Mayor","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1080\/15384047.2018.1538614","article-title":"Unique Genomic Profiles Obtained from Cerebrospinal Fluid Cell-Free DNA of Non-Small Cell Lung Cancer Patients with Leptomeningeal Metastases","volume":"20","author":"Ying","year":"2019","journal-title":"Cancer Biol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnen\/nly046","article-title":"Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease","volume":"77","author":"Ballester","year":"2018","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1158\/1535-7163.MCT-15-0712","article-title":"BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System","volume":"15","author":"Janku","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","article-title":"Clinical and Molecular Response to Tebentafusp in Previously Treated Patients with Metastatic Uveal Melanoma: A Phase 2 Trial","volume":"28","author":"Carvajal","year":"2022","journal-title":"Nat. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1158\/1078-0432.CCR-22-2434","article-title":"Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases","volume":"29","author":"Wijetunga","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e2120040","DOI":"10.1001\/jamanetworkopen.2021.20040","article-title":"Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid","volume":"4","author":"White","year":"2021","journal-title":"JAMA Netw. Open."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"869108","DOI":"10.3389\/fonc.2022.869108","article-title":"Cell-Free RNA as a Novel Biomarker for Response to Therapy in Head & Neck Cancer","volume":"12","author":"Tosevska","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41598-017-00606-w","article-title":"Towards Personalized Medicine in Melanoma: Implementation of a Clinical Next-Generation Sequencing Panel","volume":"7","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e1090","DOI":"10.1002\/ctm2.1090","article-title":"Circulating Cell-Free Messenger RNA Enables Non-Invasive Pan-Tumour Monitoring of Melanoma Therapy Independent of the Mutational Genotype","volume":"12","author":"Albrecht","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41698-021-00228-6","article-title":"Comprehensive RNA Analysis of CSF Reveals a Role for CEACAM6 in Lung Cancer Leptomeningeal Metastases","volume":"5","author":"Li","year":"2021","journal-title":"NPJ Precis. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Steininger, J., Gellrich, F.F., Schulz, A., Westphal, D., Beissert, S., and Meier, F. (2021). Systemic Therapy of Metastatic Melanoma: On the Road to Cure. Cancers, 13.","DOI":"10.3390\/cancers13061430"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","article-title":"Long-Term Outcomes of Patients with Active Melanoma Brain Metastases Treated with Combination Nivolumab plus Ipilimumab (CheckMate 204): Final Results of an Open-Label, Multicentre, Phase 2 Study","volume":"22","author":"Tawbi","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_70","first-page":"iv84","article-title":"EANO-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up of Patients with Leptomeningeal Metastasis from Solid Tumours","volume":"28","author":"Weller","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11060-007-9340-4","article-title":"Breast Cancer Leptomeningeal Metastasis\u2014The Role of Multimodality Treatment","volume":"84","author":"Rudnicka","year":"2007","journal-title":"J. Neurooncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/annonc\/mdq232","article-title":"Survival of Breast Cancer Patients with Meningeal Carcinomatosis","volume":"21","author":"Gauthier","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s10549-011-1682-0","article-title":"Leptomeningeal Metastases from Breast Cancer: Intrinsic Subtypes May Affect Unique Clinical Manifestations","volume":"129","author":"Lee","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11060-010-0524-y","article-title":"Meningeal Carcinomatosis in Breast Cancer: Prognostic Factors and Outcome","volume":"104","author":"Cruz","year":"2011","journal-title":"J. Neurooncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1524-4741.2012.01228.x","article-title":"Clinical Features and Prognostic Factors in Patients with Carcinomatous Meningitis Secondary to Breast Cancer","volume":"18","author":"Crismatt","year":"2012","journal-title":"Breast J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1179\/1973947812Y.0000000034","article-title":"Prognostic Factors and Clinical Features in Patients with Leptominengeal Metastases from Breast Cancer: A Single Center Experience","volume":"24","author":"Meattini","year":"2012","journal-title":"J. Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s12032-012-0408-4","article-title":"Breast Cancer Leptomeningeal Metastasis: Propensity of Breast Cancer Subtypes for Leptomeninges and the Analysis of Factors Influencing Survival","volume":"30","author":"Rudnicka","year":"2013","journal-title":"Med. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11060-013-1175-6","article-title":"Breast Cancer and Leptomeningeal Disease (LMD): Hormone Receptor Status Influences Time to Development of LMD and Survival from LMD Diagnosis","volume":"114","author":"Garciarena","year":"2013","journal-title":"J. Neurooncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11060-013-1092-8","article-title":"A Retrospective Case Series of 103 Consecutive Patients with Leptomeningeal Metastasis and Breast Cancer","volume":"113","author":"Taillibert","year":"2013","journal-title":"J. Neurooncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/JTO.0b013e3182398e4f","article-title":"Leptomeningeal Metastasis from Non-Small Cell Lung Cancer: Survival and the Impact of Whole Brain Radiotherapy","volume":"7","author":"Morris","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.lungcan.2011.11.022","article-title":"Clinical Outcomes of Leptomeningeal Metastasis in Patients with Non-Small Cell Lung Cancer in the Modern Chemotherapy Era","volume":"76","author":"Park","year":"2012","journal-title":"Lung Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/JTO.0b013e318287c943","article-title":"Analysis of Treatment Outcomes of Intraventricular Chemotherapy in 105 Patients for Leptomeningeal Carcinomatosis from Non-Small-Cell Lung Cancer","volume":"8","author":"Gwak","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/JTO.0b013e3182773f21","article-title":"Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors","volume":"8","author":"Lee","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cllc.2013.12.009","article-title":"Prolonged Survival of Patients with Non-Small-Cell Lung Cancer with Leptomeningeal Carcinomatosis in the Modern Treatment Era","volume":"15","author":"Riess","year":"2014","journal-title":"Clin. Lung Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.lungcan.2015.05.023","article-title":"Treatment and Survival of Patients with EGFR-Mutated Non-Small Cell Lung Cancer and Leptomeningeal Metastasis: A Retrospective Cohort Analysis","volume":"89","author":"Kuiper","year":"2015","journal-title":"Lung Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1215\/15228517-2008-062","article-title":"Prognostic Factors and Outcomes in Patients with Leptomeningeal Melanomatosis","volume":"10","author":"Harstad","year":"2008","journal-title":"Neuro Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/annonc\/mdw134","article-title":"Targeted Treatment and Immunotherapy in Leptomeningeal Metastases from Melanoma","volume":"27","author":"Brandsma","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2174\/18715206113139990029","article-title":"Overcoming the Blood-Brain Barrier for Chemotherapy: Limitations, Challenges and Rising Problems","volume":"14","author":"Wang","year":"2014","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11060-012-0879-3","article-title":"Phase II Trial of Temozolomide for Leptomeningeal Metastases in Patients with Solid Tumors","volume":"109","author":"Segura","year":"2012","journal-title":"J. Neurooncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"E1540","DOI":"10.1073\/pnas.1714089115","article-title":"Anti-PD-1\/Anti-CTLA-4 Efficacy in Melanoma Brain Metastases Depends on Extracranial Disease and Augmentation of CD8+ T Cell Trafficking","volume":"115","author":"Taggart","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Van Bussel, M.T.J., Beijnen, J.H., and Brandsma, D. (2019). Intracranial Antitumor Responses of Nivolumab and Ipilimumab: A Pharmacodynamic and Pharmacokinetic Perspective, a Scoping Systematic Review. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5741-y"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1212\/WNL.0000000000002298","article-title":"Choroid Plexus--CSF System: Recent Developments and Clinical Correlations","volume":"86","author":"Benarroch","year":"2016","journal-title":"Neurology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jpba.2018.10.025","article-title":"Enzyme Linked Immunosorbent Assay for the Quantification of Nivolumab and Pembrolizumab in Human Serum and Cerebrospinal Fluid","volume":"164","author":"Pluim","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.cad.0000236313.50833.ee","article-title":"Ratio of Trastuzumab Levels in Serum and Cerebrospinal Fluid Is Altered in HER2-Positive Breast Cancer Patients with Brain Metastases and Impairment of Blood-Brain Barrier","volume":"18","author":"Stemmler","year":"2007","journal-title":"Anticancer Drugs"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.1038\/s41467-021-25860-5","article-title":"Genomic and Transcriptomic Correlates of Immunotherapy Response within the Tumor Microenvironment of Leptomeningeal Metastases","volume":"12","author":"Prakadan","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"9508","DOI":"10.1200\/JCO.2021.39.15_suppl.9508","article-title":"Five-Year Overall Survival from the Anti-PD1 Brain Collaboration (ABC Study): Randomized Phase 2 Study of Nivolumab (Nivo) or Nivo+ipilimumab (Ipi) in Patients (Pts) with Melanoma Brain Metastases (Mets)","volume":"39","author":"Long","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.1038\/s41467-021-25859-y","article-title":"Phase II Study of Ipilimumab and Nivolumab in Leptomeningeal Carcinomatosis","volume":"12","author":"Brastianos","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-020-0918-0","article-title":"Single-Arm, Open-Label Phase 2 Trial of Pembrolizumab in Patients with Leptomeningeal Carcinomatosis","volume":"26","author":"Brastianos","year":"2020","journal-title":"Nat. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e002473","DOI":"10.1136\/jitc-2021-002473","article-title":"Pembrolizumab for Patients with Leptomeningeal Metastasis from Solid Tumors: Efficacy, Safety, and Cerebrospinal Fluid Biomarkers","volume":"9","author":"Naidoo","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF Gene in Human Cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/CMR.0b013e32835e589c","article-title":"Long-Term Stabilization of Leptomeningeal Disease with Whole-Brain Radiation Therapy in a Patient with Metastatic Melanoma Treated with Vemurafenib: A Case Report","volume":"23","author":"Lee","year":"2013","journal-title":"Melanoma Res."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Kim, D.W., Barcena, E., Mehta, U.N., Rohlfs, M.L., Kumar, A.J., Penas-Prado, M., and Kim, K.B. (2015). Prolonged Survival of a Patient with Metastatic Leptomeningeal Melanoma Treated with BRAF Inhibition-Based Therapy: A Case Report. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1391-x"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s11060-017-2472-2","article-title":"Rapid Resolution of Leptomeningeal Disease with Targeted Therapy in a Metastatic Melanoma Patient","volume":"133","author":"Glitza","year":"2017","journal-title":"J. Neurooncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1586\/era.13.33","article-title":"Revisiting the Role of Systemic Therapies in Patients with Metastatic Melanoma to the CNS","volume":"13","author":"Januszewski","year":"2013","journal-title":"Expert. Rev. Anticancer Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1124\/jpet.112.201475","article-title":"Mechanisms Limiting Distribution of the Threonine-Protein Kinase B-RaF(V600E) Inhibitor Dabrafenib to the Brain: Implications for the Treatment of Melanoma Brain Metastases","volume":"344","author":"Mittapalli","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.2174\/138161211797440186","article-title":"Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up","volume":"17","author":"Agarwal","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.apsb.2013.12.001","article-title":"The Pharmacological Impact of ATP-Binding Cassette Drug Transporters on Vemurafenib-Based Therapy","volume":"4","author":"Wu","year":"2014","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and Function of the Blood-Brain Barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1021\/mp500435s","article-title":"Role of P-Glycoprotein on the Brain Penetration and Brain Pharmacodynamic Activity of the MEK Inhibitor Cobimetinib","volume":"11","author":"Choo","year":"2014","journal-title":"Mol. Pharm."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/jpet.112.192195","article-title":"Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the Brain Distribution of a Novel BRAF Inhibitor: Vemurafenib (PLX4032)","volume":"342","author":"Mittapalli","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1021\/mp3003144","article-title":"Oral Availability and Brain Penetration of the B-RAFV600E Inhibitor Vemurafenib Can Be Enhanced by the P-GLYCOprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar","volume":"9","author":"Durmus","year":"2012","journal-title":"Mol. Pharm."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40495-016-0072-z","article-title":"Challenges in the Delivery of Therapies to Melanoma Brain Metastases","volume":"2","author":"Gampa","year":"2016","journal-title":"Curr. Pharmacol. Rep."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/CMR.0000000000000162","article-title":"Cerebrospinal Fluid Concentrations of Vemurafenib in Patients Treated for Brain Metastatic BRAF-V600 Mutated Melanoma","volume":"25","author":"Templier","year":"2015","journal-title":"Melanoma Res."},{"key":"ref_114","unstructured":"MD Anderson Cancer Center (2023). Phase II Study of Binimetinib With Encorafenib in Patients with Metastatic Melanoma and CNS Metastases, MD Anderson Cancer Center."},{"key":"ref_115","unstructured":"Pfizer (2023). A Two-Part, Phase 1a\/B, Open-Label, Multicenter Trial Evaluating Pharmacokinetics, Safety and Efficacy of pf-07284890 (Arry 461) in Participants with Braf V600 Mutant Solid Tumors with and without Brain Involvement, Pfizer."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1158\/1078-0432.CCR-21-2761","article-title":"Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor","volume":"28","author":"Wichmann","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_117","first-page":"1079","article-title":"Leptomeningeal Metastasis in Melanoma: A Prospective Clinical Study of Nine Patients","volume":"26","author":"Pape","year":"2012","journal-title":"In Vivo"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e000283","DOI":"10.1136\/esmoopen-2017-000283","article-title":"Retrospective Review of Metastatic Melanoma Patients with Leptomeningeal Disease Treated with Intrathecal Interleukin-2","volume":"3","author":"Glitza","year":"2018","journal-title":"ESMO Open"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41591-022-02170-x","article-title":"Concurrent Intrathecal and Intravenous Nivolumab in Leptomeningeal Disease: Phase 1 Trial Interim Results","volume":"29","author":"Ferguson","year":"2023","journal-title":"Nat. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e000507","DOI":"10.1136\/esmoopen-2019-000507","article-title":"How We Treat Patients with Leptomeningeal Metastases","volume":"4","author":"Preusser","year":"2019","journal-title":"ESMO Open"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/neuonc\/not114","article-title":"Memantine for the Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"15","author":"Brown","year":"2013","journal-title":"Neuro Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1200\/JCO.2014.57.2909","article-title":"Preservation of Memory with Conformal Avoidance of the Hippocampal Neural Stem-Cell Compartment during Whole-Brain Radiotherapy for Brain Metastases (RTOG 0933): A Phase II Multi-Institutional Trial","volume":"32","author":"Gondi","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.22.01148","article-title":"Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis","volume":"40","author":"Yang","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/neuonc\/noaa152","article-title":"Clinical Trial of Proton Craniospinal Irradiation for Leptomeningeal Metastases","volume":"23","author":"Yang","year":"2021","journal-title":"Neuro Oncol."},{"key":"ref_125","unstructured":"University of Aarhus (2023). Phase II Study of Proton Cranio-Spinal Irradiation for Leptomeningeal Metastasis, University of Aarhus."},{"key":"ref_126","unstructured":"University of Zurich (2022). Intrathecal Administration of Anti-PD1\/Anti-CTLA-4 in Combination with Systemic Combination of Anti-PD1\/Anti-CTLA-4 in Patients with NSCLC without Oncogenic Driver Mutation or Melanoma and Newly Diagnosed Leptomeningeal Metastasis: A Multicentric Phase I Study, University of Zurich."},{"key":"ref_127","unstructured":"Mall, H. (2021). Phase II Trial of Pembrolizumab and Lenvatinib for Leptomeningeal Metastases, Dana-Farber Cancer Institute."},{"key":"ref_128","unstructured":"Merck Sharp & Dohme LLC (2023). A Phase 3 Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080\/MK-7902) versus Pembrolizumab Alone as First-Line Intervention in Participants with Advanced Melanoma (LEAP-003), Merck Sharp & Dohme LLC."},{"key":"ref_129","unstructured":"Merck Sharp & Dohme LLC (2022). A Multicenter, Open-Label, Phase 2 Trial to Assess the Efficacy and Safety of Lenvatinib (E7080\/MK-7902) in Combination with Pembrolizumab (MK-3475) in Participants with Advanced Melanoma Previously Exposed to an Anti-PD-1\/L1 Agent (LEAP-004), Merck Sharp & Dohme LLC."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.22.00221","article-title":"Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma with Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination","volume":"41","author":"Arance","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_131","unstructured":"SWOG Cancer Research Network (2023). A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases, SWOG Cancer Research Network."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1124\/dmd.117.079194","article-title":"Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases","volume":"46","author":"Gampa","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s10637-018-0668-8","article-title":"E6201, an Intravenous MEK1 Inhibitor, Achieves an Exceptional Response in BRAF V600E-Mutated Metastatic Malignant Melanoma with Brain Metastases","volume":"37","author":"Babiker","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_134","unstructured":"Mayo Clinic (2023). Phase 1 Study of E6201 Plus Dabrafenib for the Treatment of Central Nervous System (CNS) Metastases from BRAF V600-Mutated Metastatic Melanoma, Mayo Clinic."},{"key":"ref_135","unstructured":"Plus Therapeutics (2022). A Dual Phase 1\/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC# 12-02), Plus Therapeutics."},{"key":"ref_136","first-page":"iii10","article-title":"LMD-14. Preclinical Safety and Activity of Intraventricular Rhenium-186 Nanoliposome (186RNL) for Leptomeningeal Metastases","volume":"3","author":"Balinda","year":"2021","journal-title":"Neurooncol. Adv."},{"key":"ref_137","unstructured":"Istituto Clinico Humanitas (2023). Prospective Double Arm. Randomized Trial for Patients with Multiple Brain Metastasis and\/or Leptomeningeal Carcinomatosis: Comparison of WBRT Alone and WBRT Plus Silibinin (Sillbrain), Istituto Clinico Humanitas."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Verdura, S., Cuy\u00e0s, E., Ruiz-Torres, V., Micol, V., Joven, J., Bosch-Barrera, J., and Menendez, J.A. (2021). Lung Cancer Management with Silibinin: A Historical and Translational Perspective. Pharmaceuticals, 14.","DOI":"10.3390\/ph14060559"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/s41591-018-0044-4","article-title":"STAT3 Labels a Subpopulation of Reactive Astrocytes Required for Brain Metastasis","volume":"24","author":"Priego","year":"2018","journal-title":"Nat. Med."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Pan, Z. (2022). An Open-Label, Randomized, Multicenter Trial of Intrathecal-Pemetrexed Combined with Concurrent Involved-Field Radiotherapy and Intrathecal-Pemetrexed Alone in Patients with Leptomeningeal Metastasis from Solid Tumors, Clinicaltrials.gov.","DOI":"10.1016\/j.radonc.2023.109740"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.jtho.2021.04.018","article-title":"Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1\/2 Clinical Trial (Unique Identifier: ChiCTR1800016615)","volume":"16","author":"Fan","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1126\/science.aaz2193","article-title":"Cancer Cells Deploy Lipocalin-2 to Collect Limiting Iron in Leptomeningeal Metastasis","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"key":"ref_143","unstructured":"Memorial Sloan Kettering Cancer Center (2022). A Phase 1a\/1b Trial of Intrathecal Deferoxamine for Leptomeningeal Metastases, Memorial Sloan Kettering Cancer Center."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/14\/11443\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:12:00Z","timestamp":1760127120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/14\/11443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":143,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ijms241411443"],"URL":"https:\/\/doi.org\/10.3390\/ijms241411443","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,14]]}}}